Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute

Videos

Inavolisib vs Alpelisib Plus Fulvestrant For Patients With PIK3CA-Mutated Advanced Breast Cancer

09/24/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...

Demetria Smith-Graziani, MD,...

09/24/2024

Oncology

Videos

First-Line Capivasertib Plus Paclitaxel Fails to Improve OS in Metastatic Triple-Negative Breast Cancer

09/16/2024

Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.

Heather McArthur, MD, discusses...

09/16/2024

Oncology

Videos

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer

09/15/2024

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...

Peter Schmid, MD, PhD, discusses...

09/15/2024

Oncology

Videos

Inavolisib Plus Palbociclib and Fulvestrant for Patients With Relapsed PIK3CA-Mutated Advanced Breast Cancer

09/03/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...

Demetria Smith-Graziani, MD,...

09/03/2024

Oncology

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

Trastuzumab Deruxtecan Maintains Superiority Over Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer

06/20/2024

Erika Hamilton, MD

Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...

Erika Hamilton, MD discusses the...

06/20/2024

Oncology

Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD

Roundtables

Managing Patients With HER2-Positive Metastatic Breast Cancer

06/17/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.

In this video, a panel of...

06/17/2024

Oncology

Roundtables

Sequencing Antibody Drug Conjugates for Patients With HER2-Low Metastatic Breast Cancer

06/17/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the sequencing of antibody drug conjugates of patients with HER2-low metastatic breast cancer, including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan.

In this video, a panel of...

06/17/2024

Oncology

Roundtables

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/14/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the management of patients with HER2-low metastatic breast cancer, sharing data from the DESTINY-Breast06 trial.

In this video, a panel of...

06/14/2024

Oncology

Kevin Kalinsky, MD, Winship Cancer Institute

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Rebecca Shatsky, MD, University of California, San Diego

Videos

Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer

06/07/2024

Rebecca Shatsky, MD

Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.

Rebecca Shatsky, MD, shares...

06/07/2024

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology